How much does Wegovy cost without insurance?

List price runs ~$1,350/mo at retail. NovoCare Pharmacy cash-pay direct from Novo Nordisk is $499/mo for all dose strengths. The Wegovy Savings Offer caps copay at $0-$225/mo for commercially insured patients depending on coverage status (not a flat $225 for everyone).

Is Ozempic the same as Wegovy?

Same active molecule (semaglutide), different FDA indications and maximum doses. Ozempic = type 2 diabetes, max 2 mg/week. Wegovy = chronic weight management, max 2.4 mg/week. Insurance pathways are very different.

Can I still get compounded GLP-1 in 2026?

For semaglutide: no — FDA declared the shortage resolved February 21, 2025 and 503A compounding is no longer broadly permitted. For tirzepatide: shortage resolved October 2024 (re-affirmed December 2024), with a wind-down enforcement window that ended in 2025. Some clinics still market "compounded" formulations with added ingredients (B12, glycine) as personalized prescriptions; the legal status is contested.

How does Wegovy compare to Saxenda?

Both are GLP-1 agonists from Novo Nordisk. Wegovy (semaglutide, weekly) produces ~15% mean weight loss; Saxenda (liraglutide, daily) produces ~6-8%. Wegovy is also cheaper per kg-lost, more convenient, and has cardiovascular outcome data (SELECT trial). Saxenda was first approved for adolescents (2020); Wegovy followed in 2022 — both are available for ages 12-17.

Aetna appeal guide

Aetna Wegovy coverage appeal

Aetna uses specific clinical-policy criteria for Wegovy. Most denials come from undocumented BMI history or missing step-therapy notes. Here is how to address both.

Aetna prior authorization criteria for Wegovy

BMI documentation ≥30 (or ≥27 with weight-related comorbidity)
6-month documented lifestyle intervention
Failure of or contraindication to at least one prior weight-loss medication
Active monitoring plan with prescriber

Aetna Wegovy policy bulletin

Step-by-step appeal flow

1
Pull your carrier policy bulletin
Aetna publishes its Wegovy coverage criteria. Read it first — every successful appeal cites it back to the reviewer.
2
Document your medical necessity
BMI documentation ≥30 (or ≥27 with weight-related comorbidity) 6-month documented lifestyle intervention Failure of or contraindication to at least one prior weight-loss medication Active monitoring plan with prescriber
3
Have your prescriber submit the PA
Most Aetna PAs go through CoverMyMeds or the carrier portal. Your prescriber attaches BMI history, comorbidities (with ICD-10 codes), lifestyle program participation, and prior weight-loss attempts.
4
If denied — file the appeal within 60 days
Emphasize medical necessity per Aetna Clinical Policy Bulletin 0794. Cite STEP-1 or SURMOUNT-1 efficacy and the patient's specific comorbidity burden.
5
Submit external review if internal appeals fail
After two internal appeals, you can request external review through your state insurance commissioner. ERISA plans go through the federal external-review process.

Letter template

Customizable Aetna appeal letter

We provide a generic medical-necessity letter generator. Customize with the Aetna-specific framing above for highest first-pass success.

Generate appeal letter

Common questions readers ask

How much does Wegovy cost without insurance?: List price runs ~$1,350/mo at retail. NovoCare Pharmacy cash-pay direct from Novo Nordisk is $499/mo for all dose strengths. The Wegovy Savings Offer caps copay at $0-$225/mo for commercially insured patients depending on coverage status (not a flat $225 for everyone).
Is Ozempic the same as Wegovy?: Same active molecule (semaglutide), different FDA indications and maximum doses. Ozempic = type 2 diabetes, max 2 mg/week. Wegovy = chronic weight management, max 2.4 mg/week. Insurance pathways are very different.
Can I still get compounded GLP-1 in 2026?: For semaglutide: no — FDA declared the shortage resolved February 21, 2025 and 503A compounding is no longer broadly permitted. For tirzepatide: shortage resolved October 2024 (re-affirmed December 2024), with a wind-down enforcement window that ended in 2025. Some clinics still market "compounded" formulations with added ingredients (B12, glycine) as personalized prescriptions; the legal status is contested.
How does Wegovy compare to Saxenda?: Both are GLP-1 agonists from Novo Nordisk. Wegovy (semaglutide, weekly) produces ~15% mean weight loss; Saxenda (liraglutide, daily) produces ~6-8%. Wegovy is also cheaper per kg-lost, more convenient, and has cardiovascular outcome data (SELECT trial). Saxenda was first approved for adolescents (2020); Wegovy followed in 2022 — both are available for ages 12-17.

Editorial information based on published Aetna coverage policies as of 2026. Your specific plan benefits may differ — confirm with your insurance card’s member services number. Not legal advice.